Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...

HIV prevention pills are no different. The good news is PrEP (pre-exposure prophylaxis) is extremely effective and generally ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

The Supreme Court on Friday rejected a challenge to the structure of a Department of Health and Human Services task force ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...